HC Wainwright Boosts Earnings Estimates for Nuvectis Pharma

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – HC Wainwright boosted their Q3 2026 earnings per share (EPS) estimates for Nuvectis Pharma in a note issued to investors on Tuesday, August 4th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.23) per share for the quarter, up from their prior forecast of ($0.26). HC Wainwright has a “Buy” rating and a $39.00 price objective on the stock. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($0.96) per share. HC Wainwright also issued estimates for Nuvectis Pharma’s Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.02) EPS, FY2027 earnings at ($1.10) EPS and FY2028 earnings at ($1.24) EPS.

Nuvectis Pharma (NASDAQ:NVCT) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.04).

A number of other analysts have also recently commented on NVCT. Roth Capital upped their price target on shares of Nuvectis Pharma from $20.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, July 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvectis Pharma in a research report on Friday, June 5th. UBS Group set a $33.00 target price on Nuvectis Pharma in a research report on Monday, July 6th. Finally, Wall Street Zen upgraded Nuvectis Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Nuvectis Pharma currently has an average rating of “Hold” and a consensus price target of $35.00.

Nuvectis Pharma Trading Down 4.2%

Shares of NVCT stock opened at $19.26 on Thursday. Nuvectis Pharma has a 1-year low of $5.55 and a 1-year high of $29.27. The stock has a market cap of $510.97 million, a price-to-earnings ratio of -14.70 and a beta of -0.26. The stock has a 50-day moving average of $17.02 and a 200-day moving average of $11.78.

Hedge Funds Weigh In On Nuvectis Pharma

Institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. bought a new position in shares of Nuvectis Pharma in the 1st quarter worth $446,000. Jane Street Group LLC bought a new stake in Nuvectis Pharma during the 1st quarter valued at $413,000. Geode Capital Management LLC raised its holdings in Nuvectis Pharma by 110.8% during the second quarter. Geode Capital Management LLC now owns 285,332 shares of the company’s stock worth $2,132,000 after buying an additional 149,999 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Nuvectis Pharma by 3,398.9% during the second quarter. JPMorgan Chase & Co. now owns 6,263 shares of the company’s stock worth $47,000 after buying an additional 6,084 shares during the last quarter. Finally, New York State Common Retirement Fund bought a new position in shares of Nuvectis Pharma in the second quarter valued at $97,000. 96.77% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, major shareholder Marlio Charles Mosseri acquired 50,000 shares of the business’s stock in a transaction dated Tuesday, June 30th. The shares were bought at an average price of $18.32 per share, with a total value of $916,000.00. Following the transaction, the insider directly owned 3,186,576 shares of the company’s stock, valued at $58,378,072.32. This trade represents a 1.59% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Ron Bentsur bought 12,500 shares of Nuvectis Pharma stock in a transaction dated Tuesday, June 30th. The stock was purchased at an average price of $20.00 per share, with a total value of $250,000.00. Following the completion of the purchase, the chief executive officer owned 3,688,424 shares in the company, valued at $73,768,480. This trade represents a 0.34% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 28.55% of the stock is currently owned by corporate insiders.

Nuvectis Pharma Company Profile

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.